Lartruvo (olaratumab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 34 Diseases   3 Trials   3 Trials   560 News 


123456»
  • ||||||||||  Yondelis (trabectedin) / PharmaMar, J&J, Lartruvo (olaratumab) / Eli Lilly, Avastin (bevacizumab) / Roche
    THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER. () -  Nov 9, 2024 - Abstract #CTOS2024CTOS_665;    
    Particularly, the combination treatment TZ/BV demonstrated high response rates and extended progression-free intervals in our population, including heavily pre-treated patients, with no significant toxicity. These findings provide a potential rationale for the earlier use of this treatment strategy in patients with SFT.
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
    Journal:  Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients. (Pubmed Central) -  Jun 9, 2023   
    Our investigation reaffirms the importance of doxorubicin in advanced soft tissue sarcoma. In the first-line setting, the results of this trial were pivotal for numerous reasons; Doxorubicin-Trabectedin is the first combination that has been proven to be more effective in terms of PFS, ORR and trend of OS compared with doxorubicin alone; moreover, it is clear that trials regarding soft tissue sarcoma should strive to be histology-driven.
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Trial completion, Trial completion date, Metastases:  KEYNOTE-505: A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) -  Apr 13, 2023   
    P1a/1b,  N=38, Completed, 
    In the first-line setting, the results of this trial were pivotal for numerous reasons; Doxorubicin-Trabectedin is the first combination that has been proven to be more effective in terms of PFS, ORR and trend of OS compared with doxorubicin alone; moreover, it is clear that trials regarding soft tissue sarcoma should strive to be histology-driven. Active, not recruiting --> Completed | Trial completion date: May 2023 --> Feb 2023
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Anticancer Drugs Associated Fanconi Syndrome: An Analysis of the FDA Adverse Event Reporting System () -  Mar 9, 2023 - Abstract #ISPOR2023ISPOR_148;    
    Olaratumab showed the highest positive signal of ROR 407.945 followed by ifosfamide (ROR 116.046). On analysis, the data identified signals for fanconi syndrome are associated with the use of anticancer drugs, but more research with a superior epidemiological study design of a defined population is required to validate these findings.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    P3 data, Journal, HEOR:  Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial. (Pubmed Central) -  May 14, 2022   
    Patients with advanced or metastatic sarcoma reported a relatively rapid decline in PROs during doxorubicin-based treatment, with patients with poorer symptoms at baseline (specifically fatigue), subsequently receiving less doxorubicin therapy. The availability of detailed summary data from the patient perspective during doxorubicin-based treatment may inform future care of these patients and can provide a resource for the development of PRO endpoints in future trials.
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly, iniparib (BSI 201) / Sanofi
    Clinical, Journal:  Fooled by randomness. The misleading effect of treatment crossover in randomized trials of therapies with marginal treatment benefit. (Pubmed Central) -  Jan 21, 2022   
    No abstract available Crossover can bias clinical outcomes of randomized clinical trials by increasing the risk of both type I (false positive) and type II (false negative) error.To show how crossover can increase type I error, we provide computer simulation and review herein illustrative examples (iniparib, olaratumab) of recently reported RCTs that demonstrated false positive treatment efficacy signals due to crossover.The ethic issues associated to crossover are also discussed.
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Trial completion, Trial completion date, Metastases:  A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Jan 11, 2022   
    P1b,  N=184, Completed, 
    Crossover can bias clinical outcomes of randomized clinical trials by increasing the risk of both type I (false positive) and type II (false negative) error.To show how crossover can increase type I error, we provide computer simulation and review herein illustrative examples (iniparib, olaratumab) of recently reported RCTs that demonstrated false positive treatment efficacy signals due to crossover.The ethic issues associated to crossover are also discussed. Active, not recruiting --> Completed | Trial completion date: Nov 2021 --> Jun 2021
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    FRAGILITY INDEX OF CLINICAL TRIALS FOR SYSTEMIC TREATMENT OF SOFT TISSUE SARCOMA ([VIRTUAL]) -  Nov 26, 2021 - Abstract #CTOS2021CTOS_339;    
    These results emphasize the importance of real-world analyses and confirmatory randomized trials following registration trials in soft tissue sarcoma. The FI can serve to complement internationally agreed value scales such as ESMO Magnitude of Clinical Benefit scale (MCBS) or ASCO value framework for the evaluation of clinical benefit of systemic treatments in advanced STS.
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Journal:  HCMV modulates c-Mpl/IEX-1 pathway-mediated megakaryo/thrombopoiesis via PDGFRα and αvβ3 receptors after allo-HSCT. (Pubmed Central) -  Nov 12, 2021   
    After treatment with inhibitors of PDGFRα and αvβ3, the HCMV infection rate in MKs was significantly reduced, suggesting that IMC-3G3 and anti-αvβ3 are potential therapeutic alternatives for viral infection. In summary, our study proposes a possible mechanism and potential treatments for thrombocytopenia caused by HCMV infection and other viral diseases associated with abnormal hemostasis.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma (clinicaltrials.gov) -  Sep 24, 2021   
    P1,  N=23, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2021 --> Apr 2021 Recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 | Trial primary completion date: Dec 2021 --> Jul 2021